RDYDr. Reddy's Laboratories Ltd.
$11.66
$0.90
(7.17%)
EarningsJul 22
Mkt Cap$10.46B
Vol643,654.00
Full Transcript: Dr Reddy's Laboratories Q4 2026 Earnings Call
Dr Reddy's Laboratories (NYSE:RDY) released fourth-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below.
Benzinga APIs provide real-time access to earnings callread more...
Benzinga
Dr. Reddys Laboratories Limited Announces Filing of Annual Report on Form 20-F
Dr. Reddys Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as Dr. Reddys) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial...
Business Wire
Dr. Reddys Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif, in the United States
Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States, expanding its oncology portfolio and...
Business Wire
NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY
NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY PR Newswire NEW YORK, May 29, 2026 NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, May 29, 2026 /PRNewswire/ -- The New...
PR Newswire
Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as Dr. Reddys), a global pharmaceutical company, today announced...
Business Wire
Dr. Reddy's Q4 Earnings and Revenues Miss Estimates, Stock Down
RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.
Zacks
Dr. Reddy's Laboratories (RDY) to Release Earnings on Tuesday
Dr. Reddy's Laboratories (NYSE:RDY) will be releasing its Q4 25/26 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...
MarketBeat
Aikya Investment Management Ltd Has $103.03 Million Position in Dr. Reddy's Laboratories Ltd $RDY
Aikya Investment Management Ltd grew its holdings in shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 9.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,338,525 shares of the...
MarketBeat
AMPH vs. RDY: Which Stock Should Value Investors Buy Now?
AMPH vs. RDY: Which Stock Is the Better Value Option?
Zacks
Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada
Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as Dr. Reddys), a global pharmaceutical company, today announced...
Business Wire
<
1
2
...
>
Advertisement|Remove ads.
Latest RDY News
ViewFull Transcript: Dr Reddy's Laboratories Q4 2026 Earnings Call
Benzinga
Dr. Reddys Laboratories Limited Announces Filing of Annual Report on Form 20-F
Business Wire
Dr. Reddys Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif, in the United States
Business Wire
Advertisement|Remove ads.